Monograph Details
|
|
Central Nervous System
> ADHD/narcolepsy
|
|
METADATE ER |
| Manufacturer |
|
UCB Inc. |
| Legal Classification |
|
CII |
| Pharmacological Class |
|
Stimulant. |
| Generic Name |
|
Methylphenidate HCl 10mg, 20mg; ext-rel tabs; dye-free. |
| Also |
|
• METADATE CD
|
| Indications |
|
Attention deficit hyperactivity disorder. Narcolepsy. |
| Adults and Children |
|
Swallow whole. <6 years: not recommended. ≥6 years: may use Metadate ER tabs in place of immediate-release products when the 8-hour dose of Metadate ER corresponds to the titrated 8-hour dose of immediate-release product; max 60mg daily. |
| Contraindications |
|
During or within 14 days of MAOIs. Marked anxiety, tension, agitation. Severe depression. Psychosis. History of aggression. Suicidal tendency. Severe hypertension. Angina. Cardiac arrhythmias. Heart failure. Recent MI. Hyperthyroidism. Thyrotoxicosis. Glaucoma. History of tics or Tourette's syndrome in patient or family. |
| Precautions |
|
Discontinue if seizures or agitation occur. Reduce dose or discontinue if paradoxical worsening of symptoms occurs. Reassess periodically. Reevaluate therapy at puberty. Hypertension. Seizure disorders. Normal fatigue states. Emotionally unstable (eg, drug or alcohol abusers). Abuse potential. May exacerbate behavior disturbances, thought disorders. Monitor growth, BP, CBC, differential, and platelet counts. Interrupt therapy if growth suppression occurs. Structural cardiac abnormalities: see literature. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
See Contraindications. Caution with pressor agents, α2-agonists (eg, clonidine). May increase levels of anticonvulsants, oral anticoagulants, tricyclics, SSRIs, phenylbutazone. Antagonizes guanethidine. |
| Adverse Reactions |
|
Headache, anorexia, abdominal pain, insomnia, nervousness, CNS overstimulation, weight loss, nausea, dizziness, dyskinesias, hypertension, tachycardia, arrhythmias, Tourette's syndrome, toxic psychosis, seizures, blood dyscrasias, rash, visual disturbances. |
| How Supplied |
CD—100
ER—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
